Sermorelin vs Hexarelin: Head-to-Head Comparison
Sermorelin is a GHRH analog with former FDA approval and a physiological release pattern, while hexarelin is the most potent GHRP but carries rapid desensitization risk. Sermorelin is better suited for long-term protocols, while hexarelin may be useful for short-term intensive GH release.
Side-by-Side Comparison
| Dimension | Sermorelin | Hexarelin |
|---|---|---|
| Evidence Level | Formerly FDA-approved; decades of data | Extensive clinical data including cardiac studies |
| FDA Status | Previously FDA-approved | Not approved |
| Mechanism | GHRH receptor agonist | Ghrelin receptor agonist (most potent GHRP) |
| GH Release Potency | Moderate, physiological | Very high; strongest GHRP |
| Desensitization Risk | Low; suitable for long-term use | High; rapid tachyphylaxis |
| Side Effects | Flushing, headache, mild injection pain | Cortisol/prolactin elevation, water retention |
| Unique Benefits | Physiological GH release, well-characterized safety | Cardioprotective effects in heart failure patients |
Peptide Overviews
Sermorelin
AFDA ApprovedSermorelin is the shortest fully functional fragment of GHRH (amino acids 1-29). It was the first GHRH analog approved by the FDA, marketed as Geref for diagnostic and therapeutic use.
Hexarelin
BHuman StudiesHexarelin is one of the most potent synthetic GH secretagogues. Research also suggests it has direct cardioprotective effects independent of its GH-releasing properties.
Sermorelin vs Hexarelin: FAQ
Stay Informed on Peptide Research
Get weekly comparison updates, new study alerts, and regulatory changes.
No spam. Unsubscribe anytime.
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.